Skip to main content
. 2017 Jul 28;17:144. doi: 10.1186/s12883-017-0911-5

Table 2.

Cognitive status and Neuropsychiatric Inventory among dementia patients

SIVD AD
All (n = 24) CDR = 0.5 (n = 14) CDR =1 ~ 2 (n = 10) All (n = 32) CDR = 0.5 (n = 21) CDR = 1 ~ 2 (n = 11)
MMSE£££ ǂ $$$ 19.08 ± 5.04 21.07 ± 4.34 16.30 ± 4.79 21.03 ± 4.67 22.90 ± 3.75 17.45 ± 4.25
CASI£££ ǂ $$$ 61.04 ± 14.78 67.21 ± 13.16 52.40 ± 12.87 67.19 ± 15.20 73.29 ± 13.12 55.55 ± 12.04
Total score 6.42 ± 5.72 5.71 ± 6.33 7.40 ± 4.88 6.88 ± 8.87 5.19 ± 5.39 10.09 ± 12.98
Hyperactivity 0.51 ± 0.82 0.48 ± 0.94 0.55 ± 0.67 0.45 ± 0.89 0.18 ± 0.29 0.98 ± 1.35
 Agitation 0.50 ± 1.45 0.64 ± 1.74 0.30 ± 0.95 0.38 ± 1.19 0.00 ± 0.00 1.09 ± 1.87
 Disinhibition 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.19 ± 1.06 0.00 ± 0.00 0.55 ± 1.81
 Irritability 1.21 ± 1.82 1.29 ± 2.16 1.10 ± 1.29 0.91 ± 1.59 0.71 ± 1.15 1.27 ± 2.24
 Aberrant motor behavior 0.33 ± 1.63 0.00 ± 0.00 0.80 ± 2.53 0.34 ± 1.15 0.00 ± 0.00 1.00 ± 1.84
Psychosis 0.58 ± 0.78 0.57 ± 0.86 0.60 ± 0.68 0.79 ± 1.19 0.65 ± 0.75 1.06 ± 1.78
 Delusion£ 0.21 ± 0.72 0.00 ± 0.00 0.50 ± 1.08 0.63 ± 1.91 0.00 ± 0.00 1.82 ± 2.99
 Hallucination 0.08 ± 0.41 0.00 ± 0.00 0.20 ± 0.63 0.31 ± 1.15 0.10 ± 0.44 0.73 ± 1.85
 Night-time behavior 1.46 ± 2.27 1.71 ± 2.59 1.10 ± 1.79 1.44 ± 1.97 1.86 ± 2.10 0.64 ± 1.43
Affective 0.63 ± 1.10 0.79 ± 1.25 0.40 ± 0.84 1.08 ± 1.41 1.05 ± 1.40 1.14 ± 1.50
 Depression 0.58 ± 1.25 0.57 ± 1.22 0.60 ± 1.35 0.88 ± 1.50 0.76 ± 1.14 1.09 ± 2.07
 Anxiety 0.67 ± 1.52 1.00 ± 1.88 0.20 ± 0.63 1.28 ± 2.33 1.33 ± 2.20 1.18 ± 2.68
Apathy £ǂǂ 0.65 ± 0.89 0.25 ± 0.80 1.20 ± 0.72§§ 0.23 ± 0.51 0.21 ± 0.46 0.27 ± 0.61§§
 Apathy ££ǂǂ 0.96 ± 1.43* 0.07 ± 0.27 2.20 ± 1.48§§ 0.25 ± 0.62* 0.29 ± 0.72 0.18 ± 0.41§§
 Eating abnormalities 0.33 ± 1.27 0.43 ± 1.60 0.20 ± 0.63 0.22 ± 0.87 0.14 ± 0.66 0.36 ± 1.21

(1) Mean ± SD were shown. (2) Abbreviation: SIVD subcortical ischemic vascular disease, AD Alzheimer’s disease, CDR Clinical Dementia Rating, MMSE Mini-Mental State Examination, CASI Cognitive Abilities Screening Instrument, Sig. Significance.(3) T-test was used to evaluate the group difference and significant difference was defined as p value <0.05. (4) * p < 0.05 on the comparisons between all SIVD patients and all AD patients;# p < 0.05 on the comparisons between SIVD patients with CDR score = 0.5 and AD patients with CDR score = 0.5; § p < 0.05, §§ p < 0.01 on the comparisons between SIVD patients with CDR score = 1 ~ 2 and AD patients with CDR score = 1 ~ 2. (5) £ p < 0.05, ££ p < 0.01, and £££ p < 0.001 on the comparisons between patient with CDR score = 0.5 and with CDR score = 1 ~ 2 among all patients respectively. (6) ǂ p < 0.05 and ǂǂ p < 0.01 on the comparisons between patient with CDR score = 0.5 and with CDR score = 1 ~ 2 in SIVD group respectively. (7) $$$ p < .001 on the comparisons between patient with CDR score = 0.5 and with CDR score = 1 ~ 2 in AD group